Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.81 |
| ▸ | ALK | Q9UM73 | 7/20 | 0.76 |
| ▸ | IGF1R | P08069 | 6/20 | 0.54 |
| ▸ | INSR | P06213 | 4/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL574464 | 1.00 | EGFR (0.81) | EGFRALKIGF1RINSRKCNH2 | |
| SCHEMBL10207756 | 0.91 | EGFR (0.89) | EGFRALKIGF1RINSRKCNH2 | |
| SCHEMBL517458 | 0.89 | EGFR (0.82) | EGFRALKIGF1RINSRKCNH2 | |
| SCHEMBL30341887 | 0.89 | EGFR (1.00) | EGFRALKIGF1RINSR | |
| SCHEMBL517813 | 0.89 | EGFR (0.86) | EGFRALKIGF1RINSRKCNH2 | |
| SCHEMBL517288 | 0.89 | EGFR (1.00) | EGFRALKIGF1RINSR | |
| SCHEMBL517278 | 0.87 | EGFR (0.85) | EGFRALKIGF1RINSR | |
| SCHEMBL517412 | 0.87 | ALK (1.00) | EGFRALKIGF1RKCNH2 | |
| SCHEMBL29355191 | 0.87 | ALK (1.00) | EGFRALKIGF1RKCNH2 | |
| SCHEMBL518078 | 0.86 | EGFR (0.83) | EGFRALKIGF1RINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601186-A2 | 4-(1H-INDOL-3-YL)-PYRIMIDINES AS ALK INHIBITORS | AstraZeneca AB (SE) | 2013-06-12 | — | — | EP | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| WO-2012017239-A2 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ALK, BRAF, ABL1 | EGFR 40/4885ALK 1/4885IGF1R 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.